Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.98+0.19 (+1.28%)
Close on Nov 18, 2026Market cap $12.50BP/E 27.5Yield 0.57%
Dr Reddys Laboratories net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2026 it was ₹42.85B, down 24.2% from the year before. The highest annual figure on record is ₹56.54B in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹42.85B | -24.2% |
| FY2025 | Mar 31, 2025 | ₹56.54B | +1.5% |
| FY2024 | Mar 31, 2024 | ₹55.68B | +23.6% |
| FY2023 | Mar 31, 2023 | ₹45.07B | +359.6% |
| FY2018 | Mar 31, 2018 | ₹9.81B | -18.5% |
| FY2017 | Mar 31, 2017 | ₹12.04B | -39.8% |
| FY2016 | Mar 31, 2016 | ₹20.01B | – |
See a number that looks wrong?